Last €27.70 EUR
Change Today +0.022 / 0.08%
Volume 0.0
MYD On Other Exchanges
As of 2:15 AM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYD) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/4/14 - €30.50
52 Week Low
12/30/13 - €15.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MYRIAD GENETICS INC (MYD)

myriad genetics inc (MYD) Related Businessweek News

View More BusinessWeek News

myriad genetics inc (MYD) Details

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company’s molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.

1,325 Employees
Last Reported Date: 08/14/13
Founded in 1991

myriad genetics inc (MYD) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $956.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $786.9K
President of Myriad Genetic Laboratories Inc
Total Annual Compensation: $1.1M
Executive Vice President, General Counsel and...
Total Annual Compensation: $716.9K
Chief Scientific Officer
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

myriad genetics inc (MYD) Key Developments

Myriad Genetics, Inc. Announces Retirement of James Evans, Chief Financial Officer

Myriad Genetics Inc. announced that James Evans, chief financial officer of Myriad, has notified the company of his intent to retire in order to attend to family health issues. To ensure a smooth transition, Evans will continue as the company's CFO until a replacement can be found. Myriad will engage a leading executive search firm to conduct a national search and will consider both internal and external candidates for the position.

Myriad Genetics, Inc. Announces Results from Pivotal Clinical Validation Study of the Myriad myPath Melanoma Test

Myriad Genetics Inc. has announced encouraging results from a pivotal clinical validation study of the Myriad myPath Melanoma test. The Myriad myPath Melanoma test is a novel molecular test that accurately differentiates malignant melanoma from benign skin lesions with a high level of accuracy and helps physicians deliver a more objective and confident diagnosis for patients. "Unfortunately, some melanomas mimic benign skin lesions, making them very difficult to diagnose and an uncertain result is confusing for patients and clinicians.

Myriad Genetics Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 10:40 AM

Myriad Genetics Inc. Presents at Goldman Sachs 35th Annual Global Healthcare Conference, Jun-10-2014 10:40 AM. Venue: Terranea Resort in Rancho Palos Verdes, 100 Terranea Way, Los Angeles, California, United States. Speakers: Peter D. Meldrum, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYD:GR €27.70 EUR +0.022

MYD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Reference Labs Inc $30.70 USD +0.26
Foundation Medicine Inc $28.00 USD +0.97
Genomic Health Inc $27.49 USD -0.11
Imperial Innovations Group PLC 462.50 GBp +2.50
NeoGenomics Inc $5.20 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation MYD Industry Range
Price/Earnings 15.8x
Price/Sales 3.6x
Price/Book 3.8x
Price/Cash Flow 14.9x
TEV/Sales 3.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at